Temporal dynamics of cisplatin-induced endothelial senescence and its association with cognitive impairment: insights into the medial prefrontal cortex

Yue Hei, Shu Kong, Jinlong Sun, Weiping Liu, Qianfa Long, Hongmei ZhangFrontiers in Oncology 2025 · DOI

TL;DR

Chemotherapy, particularly cisplatin, can lead to "chemo-brain," a debilitating cognitive impairment. This study reveals that cisplatin first triggers senescence (a state of irreversible cell cycle arrest) in the endothelial cells lining the brain's medial prefrontal cortex (mPFC). This early vascular damage then leads to a delayed breakdown of the blood-brain barrier and neuroinflammation, ultimately causing persistent working memory deficits.

What Problem Does This Paper Address?

Chemotherapy-related cognitive impairment (CRCI), often referred to as "chemo-brain," is a significant and distressing side effect for cancer survivors, impacting memory, executive function, and processing speed. While the mechanisms behind CRCI are not fully understood, it's known that chemotherapy agents can damage the central nervous system. Cisplatin, a widely used chemotherapy drug, is particularly implicated in CRCI, with evidence suggesting it can disrupt the blood-brain barrier (BBB) and cause neuroinflammation. However, the precise temporal sequence of these events and their specific impact on brain regions critical for higher cognitive functions, like the medial prefrontal cortex (mPFC), remain unclear. This paper aims to unravel this temporal cascade, focusing on how cisplatin-induced changes in the mPFC's vascular system and inflammatory responses contribute to working memory impairment.

Methods

The researchers employed a multi-faceted approach using a mouse model (adult male C57BL/6 mice) treated with cisplatin. Key techniques included:

  • Endothelial Senescence Assessment:
    • SA-β-gal staining: A standard marker for cellular senescence, used to identify senescent endothelial cells in the mPFC.
  • ELISA: To measure the levels of senescence-associated secretory phenotype (SASP) factors (IL-6, IL-1β, TNF-α), which are released by senescent cells and contribute to inflammation.
  • Western blotting: To quantify the expression of senescence-related proteins (p16^INK4a and p21^Cip1).
  • Blood-Brain Barrier (BBB) Integrity:
    • Dextran tracer immunofluorescence: A fluorescently labeled molecule (10 kDa dextran) was injected to visualize and quantify leakage across the BBB.
  • Brain water content analysis: To assess overall brain swelling, an indicator of BBB dysfunction.
  • Western blotting: To measure the levels of tight junction proteins (Claudin-5 and ZO-1), which are crucial for maintaining BBB integrity.
  • Neuroinflammation:
    • Immunofluorescence staining: For GFAP (astrocyte marker) and Iba1 (microglia marker) to assess the activation of glial cells, the brain's immune cells.
  • Cognitive Function Assessment:
    • Novel Object Recognition (NOR) test: Evaluates the ability to distinguish between familiar and novel objects, a measure of recognition memory and indirectly, working memory.
  • Puzzle Box test: Assesses problem-solving and spatial working memory by measuring the time taken to navigate through increasingly complex mazes.
  • Modified T-maze test: A standard test for spatial working memory, measuring the rate of correct choices in a T-shaped maze.

The study design involved evaluating these parameters at multiple time points post-cisplatin treatment (0 days, 1 week, 4 weeks, 8 weeks, and 12 weeks) to establish a temporal relationship between the observed changes.

Datasets

Not discussed in the paper. The study utilized a mouse model and performed experimental measurements rather than analyzing pre-existing datasets.

Key Insights and Ideas

  • Senescence Precedes BBB Breakdown: The most striking finding is the temporal separation: endothelial cell senescence in the mPFC occurs before significant BBB disruption and neuroinflammation. This suggests that vascular aging at the cellular level is an early trigger for subsequent damage.
  • mPFC Specificity: The study specifically targets the mPFC, highlighting its vulnerability and crucial role in working memory, which is often impaired in CRCI.
  • Persistent Cognitive Deficits: Unlike the vascular and inflammatory markers that show a peak and then decline, working memory impairment persists for an extended period (up to 12 weeks), suggesting a chronic underlying issue.
  • Endothelial Senescence as a Therapeutic Target: The early onset of endothelial senescence points to it as a potential early-stage therapeutic target for mitigating CRCI, particularly for working memory deficits.

Key Results

  • Endothelial Senescence: Cisplatin treatment led to a significant increase in SA-β-gal positive area and elevated SASP factors (IL-6, IL-1β, TNF-α) in the mPFC, peaking at 1 week post-treatment. Senescence-related proteins (p16^INK4a, p21^Cip1) also showed increased expression.
  • BBB Dysfunction: Significant BBB leakage and reduced tight junction protein levels (Claudin-5, ZO-1) were observed, peaking at 4 weeks post-treatment. Brain water content also significantly increased at 4 weeks.
  • Neuroinflammation: Glial activation (astrocytes and microglia) was observed, with GFAP and Iba1 staining showing increased areas, peaking around 4 weeks and persisting, though with a decline from the peak. Microglial activation appeared to be longer-lasting than astrocyte activation.
  • Working Memory Impairment: The NOR discrimination index was significantly reduced at 4, 8, and 12 weeks. Mice took longer to enter the dark box in the Puzzle Box test, and the modified T-maze showed a significantly lower percentage of correct entries into the novel arm. This impairment was persistent throughout the observed time points.

Limitations and Future Work

  • Limitations:
    • The study primarily focused on male mice. Future research should investigate sex differences in CRCI.
  • While the study identifies a temporal cascade, the precise molecular crosstalk between endothelial senescence, BBB disruption, and glial activation needs further elucidation.
  • Future Work:
    • Targeting Endothelial Senescence: The authors suggest exploring senolytics or antioxidants to normalize BBB function by mitigating upstream drivers of senescence.
  • MSC-based Strategies: Investigating the potential of mesenchymal stem cell (MSC) secretomes to mitigate endothelial injury and inflammation.
  • Neurovascular Coupling: Further research into the changes in neurovascular coupling in the context of CRCI.
  • Combined Effects: Investigating the combined effects of neurotoxicity and vascular endothelial cells.

Summary updated

Abstract

This study delineates a temporal cascade wherein cisplatin induces early mPFC endothelial senescence with delayed BBB dysfunction and neuroinflammation, driving chronic working memory impairment, thus indicating endothelial senescence as early-stage potential target for mitigating CRCI, especially in mPFC-related working memory deficits.
BibTeX
@inproceedings{hei2025temporal,
  author = {Yue Hei and Shu Kong and Jinlong Sun and Weiping Liu and Qianfa Long and Hongmei Zhang},
  title = {{Temporal dynamics of cisplatin-induced endothelial senescence and its association with cognitive impairment: insights into the medial prefrontal cortex}},
  booktitle = {Frontiers in Oncology},
  year = {2025},
  doi = {10.3389/fonc.2025.1668372},
}
Figure